Seelos Therapeutics, Inc. (SEELQ)

Market Cap	136.00 -100.0%
Revenue (ttm)	2.01M +76.0%
Net Income	4.09M
EPS	47.06
Shares Out	1.36M
PE Ratio	0.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	445
Open	0.0001
Previous Close	n/a
Day's Range	0.0001 - 0.0001
52-Week Range	0.000001 - 0.0100
Beta	21.03
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Seelos Therapeutics

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: SEELQ